Advertisement

Amino Acids

pp 1–11 | Cite as

The additive effect of type 2 diabetes on fibrinogen, von Willebrand factor, tryptophan and threonine in people living with HIV

  • Michelle L. HarrisonEmail author
  • Anthony S. Wolfe
  • Jonathan Fordyce
  • Jamie Rock
  • Alexandra A. García
  • Julie A. Zuñiga
Original Article
  • 51 Downloads

Abstract

Chronic immune activation and ensuing inflammation that accompany HIV infection lead to adverse metabolic consequences and an increased risk of type 2 diabetes (T2D). We examined the additive effects of T2D on circulating biomarkers involved in inflammation, coagulation, and vascular function along with plasma amino acids in people living with HIV (PLWH). This cross-sectional study included PLWH with and without T2D (n = 32 total). Analyses involved a multiplex platform for circulating biomarkers and gas chromatography–vacuum ultraviolet spectroscopy for plasma amino acids. In PLWH and T2D, both fibrinogen (2.0 ± 0.6 vs 1.6 ± 0.4 µg/mL, p = 0.02) and von Willebrand factor (vWF) (40.8 ± 17.2 vs 26.7 ± 13.8 µg/mL, p = 0.02) were increased and tryptophan (47 ± 6 vs 53 ± 8 nmol/mL, p = 0.03) and threonine (102 ± 25 vs 125 ± 33 nmol/mL, p = 0.03) were decreased. Fibrinogen, as a biomarker of inflammation, and vWF, as a biomarker of endothelial dysfunction, are augmented by the combined effects of HIV and T2D and may contribute to the pathogenesis of T2D in PLWH. Chronic immune activation and inflammation compromise the integrity of the intestinal mucosa, which increases mucus production. Tryptophan metabolism is altered by a loss of intestinal membrane integrity and threonine is consumed in the production of mucus. Metabolic competition arising from increased protein synthesis in the setting of chronic inflammation along with the associated loss in intestinal membrane integrity may be a primary mechanism in the pathogenesis of T2D in PLWH and requires further investigation.

Keywords

HIV Diabetes Fibrinogen von Willebrand factor Tryptophan Threonine 

Notes

Acknowledgements

This research was supported by The St. David’s Center for Health Promotion and Disease Prevention Research in Underserved Populations provided by the University of Texas at Austin School of Nursing. The authors would like to thank our colleagues at VUV Analytics, as they provided the detector used in the amino acid identification and quantification along with valuable insight and expertise. The authors would also like to extend our appreciation to Phenomenex Inc. for providing materials used in the extraction and derivatization of the plasma free amino acids.

Funding

This research was supported by The St. David’s Center for Health Promotion and Disease Prevention Research in Underserved Populations provided by the University of Texas at Austin School of Nursing.

Compliance with ethical standards

Conflict of interest

The following author, MLH, declares a competing financial interest as her spouse was a founder and is currently the Chief Technical Officer of VUV Analytics, Inc. The remaining authors have no conflicts to disclose, financial or otherwise.

Research involving human participants

All procedures performed in studies involving human participants were in accordance with the ethical standards of the University of Texas at Austin and with the 1964 Helsinki Declaration and its later amendments.

Informed consent

Informed consent was obtained from all individual participants included in the study.

References

  1. Arildsen H, Sørensen K, Ingerslev J, Østergaard L, Laursen AL (2013) Endothelial dysfunction, increased inflammation, and activated coagulation in HIV-infected patients improve after initiation of highly active antiretroviral therapy HIV. Medicine 14:1–9Google Scholar
  2. Aukrust P et al (2000) Persistently elevated levels of von Willebrand factor antigen in HIV infection. Thromb Haemost 83:183–187Google Scholar
  3. Boyvin L, Seri KL, Ake JA, Djaman JA (2017) Lysine and threonine plasma concentrations in Ivorian patients living with human immunodeficiency virus. J AIDS HIV Res 9:194–201CrossRefGoogle Scholar
  4. Brown TT et al (2005a) Antiretroviral therapy and the prevalence and incidence of diabetes mellitus in the multicenter AIDS cohort study. Arch Intern Med 165:1179–1184CrossRefPubMedGoogle Scholar
  5. Brown TT et al (2005b) Cumulative exposure to nucleoside analogue reverse transcriptase inhibitors is associated with insulin resistance markers in the Multicenter AIDS Cohort Study. Aids 19:1375–1383CrossRefPubMedGoogle Scholar
  6. Brown TT, Tassiopoulos K, Bosch RJ, Shikuma C, McComsey GA (2010) Association between systemic inflammation and incident diabetes in HIV-infected patients after initiation of antiretroviral therapy. Diabetes care 33:2244–2249CrossRefPubMedGoogle Scholar
  7. Butt AA et al (2009) HIV infection and the risk of diabetes mellitus. AIDS (Lond Engl) 23:1227CrossRefGoogle Scholar
  8. CDC (2018) Centers for disease control and prevention. Estimated HIV incidence and prevalence in the United States, 2010–2015. HIV surveillance supplemental report 2018; 23(No. 1). http://www.cdc.gov/hiv/library/reports/hiv-surveillance.html. Published March 2018. Accessed [October 22, 2018]
  9. Committee IE (2009) International Expert Committee report on the role of the A1C assay in the diagnosis of diabetes. Diabetes care 32:1327–1334CrossRefGoogle Scholar
  10. Control CfD, Prevention (2017) National diabetes statistics report, 2017. Centers for disease control and prevention, AtlantaGoogle Scholar
  11. Davalos D, Akassoglou K (2012) Fibrinogen as a key regulator of inflammation in disease. Seminars in immunopathology, vol 1. Springer, Berlin, pp 43–62Google Scholar
  12. Davidson MB, Schriger DL (2010) Effect of age and race/ethnicity on HbA1c levels in people without known diabetes mellitus: implications for the diagnosis of diabetes. Diabetes Res Clin Pract 87:415–421CrossRefPubMedGoogle Scholar
  13. Dooko CBA, De Wit S, Neuhaus J, Palfreeman A, Pepe R, Pankow JS, Neaton JD (2014) Interleukin-6, high sensitivity C-reactive protein, and the development of type 2 diabetes among HIV positive patients taking antiretroviral therapy. J Acquir Immune Defic Synd 67:538CrossRefGoogle Scholar
  14. Duro M, Manso M, Barreira S, Rebelo I, Medeiros R, Almeida C (2018) Metabolic syndrome in human immunodeficiency virus-infected patients. Int J STD AIDS 29:1089–1097CrossRefPubMedGoogle Scholar
  15. Fan H, Smuts J, Bai L, Walsh P, Armstrong DW, Schug KA (2016) Gas chromatography–vacuum ultraviolet spectroscopy for analysis of fatty acid methyl esters. Food Chem 194:265–271CrossRefPubMedGoogle Scholar
  16. Freiberg MS et al (2013) HIV infection and the risk of acute myocardial infarction. JAMA Intern Med 173:614–622CrossRefPubMedGoogle Scholar
  17. Funderburg NT (2014) Markers of coagulation and inflammation often remain elevated in ART-treated HIV-infected patients. Curr Opin HIV AIDS 9:80CrossRefPubMedGoogle Scholar
  18. Gostner JM, Becker K, Kurz K, Fuchs D (2015) Disturbed amino acid metabolism in HIV: association with neuropsychiatric symptoms. Front Psychiatry 6:97CrossRefPubMedGoogle Scholar
  19. Herman WH, Cohen RM (2012) Racial and ethnic differences in the relationship between HbA1c and blood glucose: implications for the diagnosis of diabetes. J Clin Endocrinol Metab 97:1067–1072CrossRefPubMedGoogle Scholar
  20. Hernandez-Romieu AC, Garg S, Rosenberg ES, Thompson-Paul AM, Skarbinski J (2017) Is diabetes prevalence higher among HIV-infected individuals compared with the general population? Evidence from MMP and NHANES 2009–2010. BMJ Open Diabetes Res Care 5:e000304CrossRefPubMedGoogle Scholar
  21. Hoel H et al (2018) Impact of HIV and Type 2 diabetes on gut microbiota diversity, tryptophan catabolism and endothelial dysfunction. Sci Rep.  https://doi.org/10.1038/s41598-41018-25168-41593 PubMedGoogle Scholar
  22. Hortin GL, Landt M, Powderly WG (1994) Changes in plasma amino acid concentrations in response to HIV-1 infection. Clin Chem 40:785–789PubMedGoogle Scholar
  23. Hove-Skovsgaard M et al (2017) HIV-infected persons with type 2 diabetes show evidence of endothelial dysfunction and increased inflammation. BMC Infect Dis 17:234CrossRefPubMedGoogle Scholar
  24. Jeon JY et al (2013) Prevalence of diabetes and prediabetes according to fasting plasma glucose and HbA1c. Diabetes Metab J 37:349–357CrossRefPubMedGoogle Scholar
  25. Jong E, Meijers JC, van Gorp EC, Spek CA, Mulder JW (2010) Markers of inflammation and coagulation indicate a prothrombotic state in HIV-infected patients with long-term use of antiretroviral therapy with or without abacavir. AIDS Res Therapy 7:9CrossRefGoogle Scholar
  26. Juhan-Vague I, Thompson S, Jespersen J (1993) Involvement of the hemostatic system in the insulin resistance syndrome. A study of 1500 patients with angina pectoris. The ECAT Angina Pectoris Study Group. Arterioscler Thromb Vasc Biol 13:1865–1873CrossRefGoogle Scholar
  27. Keithley JK, Duloy AM, Swanson B, Zeller JM (2009) HIV infection and obesity: a review of the evidence. J Assoc Nurses AIDS Care 20:260–274CrossRefPubMedGoogle Scholar
  28. Kim PS, Woods C, Georgoff P, Crum D, Rosenberg A, Smith M, Hadigan C (2009) A1C underestimates glycemia in HIV infection. Diabetes Care 32:1591–1593CrossRefPubMedGoogle Scholar
  29. Knowler WC, Barrett-Connor E, Fowler SE, Hamman RF, Lachin JM, Walker EA, Nathan DM (2002) Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin. N Engl J Med 346:393–403CrossRefPubMedGoogle Scholar
  30. Kuller LH et al (2008) Inflammatory and coagulation biomarkers and mortality in patients with HIV infection. PLoS Med 5:e203CrossRefPubMedGoogle Scholar
  31. Laurichesse H et al (1998) Threonine and methionine are limiting amino acids for protein synthesis in patients with AIDS. J Nut 128:1342–1348CrossRefGoogle Scholar
  32. Le Floc’h N, Otten W, Merlot E (2011) Tryptophan metabolism, from nutrition to potential therapeutic applications. Amino Acids 41:1195–1205CrossRefPubMedGoogle Scholar
  33. Linley L, Atkins CY, Li J, Yu C, Johnson AS, Friend M (2018) Centers for Disease Control and Prevention. Diagnoses of HIV infection among adults aged 50 years and older in the United States and dependent areas, 2011–2016. HIV surveillance supplemental report 2018. http://www.cdc.gov/hiv/library/reports/hiv-surveillance.html. Accessed 15 Dec 2018
  34. Look MP et al (2000) Parallel decrease in neurotoxin quinolinic acid and soluble tumor necrosis factor receptor p75 in serum during highly active antiretroviral therapy of HIV type 1 disease. AIDS Re Hum Retroviruses 16:1215–1221CrossRefGoogle Scholar
  35. Lundgren JD et al (2008) European AIDS clinical society (EACS) guidelines on the prevention and management of metabolic diseases in HIV. HIV Med 9:72–81CrossRefPubMedGoogle Scholar
  36. Madden E et al (2008) Association of antiretroviral therapy with fibrinogen levels in HIV infection. AIDS (Lond Engl) 22:707CrossRefGoogle Scholar
  37. Meigs JB et al (2000) Hyperinsulinemia, hyperglycemia, and impaired hemostasis: the Framingham Offspring study. Jama 283:221–228CrossRefPubMedGoogle Scholar
  38. Murray MF (2003) Tryptophan depletion and HIV Tryptophan depletion and HIV infection: a metabolic link to pathogenesis. Lancet Infect Dis 3:644–652CrossRefPubMedGoogle Scholar
  39. Nakagawa F, May M, Phillips A (2013) Life expectancy living with HIV: recent estimates and future implications. Curr Opin Infect Dis 26:17–25CrossRefPubMedGoogle Scholar
  40. Neuhaus J et al (2010) Markers of inflammation, coagulation, and renal function are elevated in adults with HIV infection. J Infect Dis 201:1788–1795CrossRefPubMedGoogle Scholar
  41. Ollenschläger G, Jansen S, Schindler J, Rasokat H, Schrappe-Bächer M, Roth E (1988) Plasma amino acid pattern of patients with HIV infection. Clin Chem 34:1787–1789PubMedGoogle Scholar
  42. Preston T, Slater C, McMillan DC, Falconer JS, Shenkin A, Fearon KC (1998) Fibrinogen synthesis is elevated in fasting cancer patients with an acute phase response. J Nutr 128:1355–1360CrossRefPubMedGoogle Scholar
  43. Rémond D et al (2009) Intestinal inflammation increases gastrointestinal threonine uptake and mucin synthesis in enterally fed minipigs. J Nutr 139:720–726CrossRefPubMedGoogle Scholar
  44. Ruth MR, Field CJ (2013) The immune modifying effects of amino acids on gut-associated lymphoid tissue. J Animal Sci Biotechnol 4:27CrossRefGoogle Scholar
  45. Samaras K (2009) Prevalence and pathogenesis of diabetes mellitus in HIV-1 infection treated with combined antiretroviral therapy. JAIDS J Acquir Immune Defic Synd 50:499–505CrossRefGoogle Scholar
  46. Schug KA et al (2014) Vacuum ultraviolet detector for gas chromatography. Anal Chem 86:8329–8335CrossRefPubMedGoogle Scholar
  47. Shah SH et al (2012) Baseline metabolomic profiles predict cardiovascular events in patients at risk for coronary artery disease. Am Heart J 163(844–850):e841Google Scholar
  48. Slama L et al (2014) Inaccuracy of haemoglobin A1c among HIV-infected men: effects of CD4 cell count, antiretroviral therapies and haematological parameters. J Antimicrob Chemother 69:3360–3367CrossRefPubMedGoogle Scholar
  49. So-Armah KA et al (2016) Do biomarkers of inflammation, monocyte activation, and altered coagulation explain excess mortality between HIV infected and uninfected people? J Acquir Immune Defic Syndr 72:206CrossRefPubMedGoogle Scholar
  50. Tate T et al (2012) HIV infection and obesity: where did all the wasting go? Antiviral therapy 17:1281CrossRefPubMedGoogle Scholar
  51. Teer E, Essop MF (2017) HIV and cardiovascular disease: role of immunometabolic perturbations. Physiology 33:74–82CrossRefGoogle Scholar
  52. Tien PC et al (2007) Antiretroviral therapy exposure and incidence of diabetes mellitus in the women’s interagency HIV study. Aids 21:1739–1745CrossRefPubMedGoogle Scholar
  53. Tien PC et al (2010) Inflammation and mortality in HIV-infected adults: analysis of the FRAM study cohort. J Acquir Immune Defic Syndr 55:316CrossRefPubMedGoogle Scholar
  54. Tien PC et al (2012) Association of HIV infection with incident diabetes mellitus: impact of using hemoglobin A1C as a criterion for diabetes. J Acquir Immune Defic Syndr 61:334CrossRefPubMedGoogle Scholar
  55. UNAIDS (2013) Joint United Nations Programme on HIV/AIDS. HIV and aging: a special supplement to the UNAIDS report on the global AIDS epidemic 2013. Joint United Nations Programme on HIV/AIDS (UNAIDS). http://www.unaids.org/sites/default/files/media_asset/20131101_JC2563_hiv-and-aging_en_0.pdf. Accessed 22 Oct 2018
  56. Vujkovic-Cvijin I et al (2013) Dysbiosis of the gut microbiota is associated with HIV disease progression and tryptophan catabolism. Sci Transl Med 5:193ra191–193ra191CrossRefGoogle Scholar
  57. Wing EJ (2016) HIV and aging. Int J Infect Dis 53:61–68CrossRefPubMedGoogle Scholar
  58. Zangerle R, Widner B, Quirchmair G, Neurauter G, Sarcletti M, Fuchs D (2002) Effective antiretroviral therapy reduces degradation of tryptophan in patients with HIV-1 infection. Clin Immunol 104:242–247CrossRefPubMedGoogle Scholar
  59. Zangerle R, Kurz K, Neurauter G, Kitchen M, Sarcletti M, Fuchs D (2010) Increased blood phenylalanine to tyrosine ratio in HIV-1 infection and correction following effective antiretroviral therapy. Brain Behav Immun 24:403–408CrossRefPubMedGoogle Scholar
  60. Zhang C (2008) The role of inflammatory cytokines in endothelial dysfunction. Basic Res Cardiol 103:398–406CrossRefPubMedGoogle Scholar
  61. Ziemer DC et al (2010) Glucose-independent, black–white differences in hemoglobin A1c levels: a cross-sectional analysis of 2 studies. Ann Intern Med 152:770–777CrossRefPubMedGoogle Scholar

Copyright information

© Springer-Verlag GmbH Austria, part of Springer Nature 2019

Authors and Affiliations

  1. 1.Department of Kinesiology and Health EducationUniversity of Texas at AustinAustinUSA
  2. 2.School of NursingUniversity of TexasAustinUSA
  3. 3.Department of Population Health, Dell Medical SchoolUniversity of TexasAustinUSA

Personalised recommendations